Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D. DiNardo, Hagop M. Kantarjian, Yesid Alvarado et al.|Journal of Clinical Oncology|2021Cited by 333
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemiaGuillermo Montalban‐Bravo, Simona Colla|Cell Reports Medicine|2024Cited by 14
Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)Veronica Guerra, Koichi Takahashi, Yuanqing Yan et al.|Blood|2019Cited by 8
A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)Luca Lanino, Vladan Vučinić, Anthony M. Hunter et al.|Blood|2024Cited by 3